about
Synthetic lethality in lung cancer and translation to clinical therapiesNanoscale Reaction Vessels Designed for Synthesis of Copper-Drug Complexes Suitable for Preclinical DevelopmentContributions of conserved residues at the gating interface of glycine receptors.Combined Use of Gene Expression Modeling and siRNA Screening Identifies Genes and Pathways Which Enhance the Activity of Cisplatin When Added at No Effect Levels to Non-Small Cell Lung Cancer Cells In Vitro.Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments.In Vivo Validation of PAPSS1 (3'-phosphoadenosine 5'-phosphosulfate synthase 1) as a Cisplatin-Sensitizing Therapeutic Target.Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status.Induction of Cytotoxicity in Pyridine Analogues of the Anti-metastatic Ru(III) Complex NAMI-A by Ferrocene Functionalization.3'-Phosphoadenosine 5'-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents.Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent.Sulfonation, an underexploited area: from skeletal development to infectious diseases and cancer.A Perspective - can copper complexes be developed as a novel class of therapeutics?A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.Transition Metal Ions Promote the Bioavailability of Hydrophobic Therapeutics: Cu and Zn Interactions with RNA Polymerase I Inhibitor CX5461.Copper-CX-5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor
P50
Q28072904-8C61BAE3-0256-4693-B3B1-8C32E55D0CBFQ28551246-C96614D1-622E-4640-887A-63C770E319E2Q35266383-9D13EC51-55FE-47BC-817A-96F232E421E2Q35944751-BE02EAE3-4CFA-4C2B-9738-ABA1C5A3602EQ38205584-6A4E96B7-CA79-4989-B802-F6D470DED03BQ38633296-C30A5B7B-4C3A-4187-9180-EE87D81AD4D7Q38667138-568D97EA-A60A-40C5-8730-7C55A361EA59Q38812951-A943E02F-8FEF-466B-9867-B48C86D989CDQ38848421-B9D79EDE-E529-452A-8741-0DA47EF7C7D2Q42220334-C66B4CD2-32D6-4626-A696-4A4E08171B54Q42317502-20835C53-3052-4BB6-9B50-66D770F74483Q53165913-BDAAA2B1-13DD-4120-93A8-5A1F733FE71FQ53515991-920AE951-2F6B-4E9F-953B-26BE1A2B221FQ54982655-AD8ED126-B8B9-4AD1-BF94-787261D176FBQ90284000-B9FECEE6-21BA-4E3A-9986-DB2A2D28B037
P50
description
investigador
@es
researcher
@en
name
Ada W Y Leung
@en
type
label
Ada W Y Leung
@en
prefLabel
Ada W Y Leung
@en
P31
P496
0000-0002-8018-1248